Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HINT1 | P49773 | 4/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | PNP | P00491 | 2/20 | 0.57 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880677 | 0.92 | HPGD (0.63) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL7101380 | 0.92 | HPGD (0.60) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL545904 | 0.92 | HPGD (0.60) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14842253 | 0.92 | HPGD (0.63) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL7549552 | 0.92 | HPGD (0.60) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL12300426 | 0.91 | HPGD (0.61) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL546454 | 0.91 | HPGD (0.59) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL20582919 | 0.91 | HPGD (0.59) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL21179102 | 0.91 | HPGD (0.59) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL7614834 | 0.91 | HPGD (0.59) | HPGDHINT1NT5EPNPGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023194537-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF POLYNUCLEOTIDES INCLUDING OLIGONUCLEOTIDES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-12 | — | — | WO | disclosed |
| EP-2380897-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20040258656-A1 | High affinity TGFbeta nucleic acid ligands and inhibitors | GILEAD SCIENCES, INC. | 2004-12-23 | — | — | US | disclosed |
| US-6713616-B2 | DETECTING BINDING | GILEAD SCIENCES, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030064943-A1 | High affinity TGFbeta nucleic acid ligands and inhibitors | GILEAD SCIENCES, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6346611-B1 | AN EXOGENOUSLY OCCURRING RNA LIGAND; FOR USE AS DRUGS, DIAGNOSTICS, IMAGING AGENTS AND IMMUNOHISTOCHEMICAL REAGENTS | GILEAD SCIENCES, INC. | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064943-A1 | High affinity TGFbeta nucleic acid ligands and inhibitors | TGFBR2, TGFBR1, TGFB2 | HPGD 4463/4885HINT1 2043/4885NT5E 110/4885 |
| US-20040258656-A1 | High affinity TGFbeta nucleic acid ligands and inhibitors | TGFBR2, TGFBR1, TGFB2 | HPGD 4463/4885HINT1 2043/4885NT5E 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.